AC Immune SA (ACIU) AI Stock Analysis

• Market Cap: $225.59M
• Dividend Yield: N/A
• Average Volume (3M): 133.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 91.44%
• EPS Growth: 18.94%
• Country: US
• Employees: 133
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 98,943,130
• 10 Day Avg. Volume: 150,495
• 30 Day Avg. Volume: 133,360
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.22
• Enterprise Value/Revenue: 1.75
• Enterprise Value/Gross Profit: 1.75
• Enterprise Value/Ebitda: -1.06
• 1Y Price Target: $10.00
• Price Target Upside: 354.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: $2.00 ▼(-9.09% Downside)

AC Immune SA's stock score is primarily influenced by its financial performance and technical analysis. While the company shows potential with improving cash flow and short-term bullish momentum, persistent net losses and a negative P/E ratio weigh heavily on the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Financial stability

Cash resources of CHF 127.1 million should provide cash for operations through Q3 2027 not including potential payments from partnering.

Immunotherapy advancements

Promising immunogenicity readouts for active immunotherapies targeting both AD and PD patients suggest less cumbersome treatment approaches than monthly mAb infusions.

Pipeline progress

The company continues to advance its early-stage pipeline, including IND filing for ACI-19764 and initiation of IND-enabling studies for morphomer inhibitors.

Negative Factors

Developmental challenges

The selection of lead candidates for Morphomer Tau and Morphomer alpha-syn programs is still expected in 2H25, indicating developmental challenges.

Technical risks

There are still technical risks to these programs as each vaccine-ish therapy makes some guesses over the structure of the toxic species to be cleared.

AC Immune SA Business Overview & Revenue Model

Company Description

AC Immune SA (ACIU) is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. Established in 2003 and headquartered in Lausanne, Switzerland, the company operates primarily in the biotechnology sector. AC Immune's core products include a portfolio of immunotherapies and diagnostics aimed at targeting misfolded proteins, which play a critical role in the pathogenesis of neurodegenerative disorders. The company leverages its proprietary technologies, including its unique antibody and vaccine platforms, to advance its pipeline of drug candidates.

How the Company Makes Money

AC Immune generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates. These partnerships often include milestone payments, royalties on future sales, and upfront payments that contribute to the company's earnings. Additionally, AC Immune may receive revenue from licensing agreements related to its proprietary technologies. The company is also focused on advancing its own drug candidates through clinical trials, which, upon successful development and regulatory approval, can lead to significant sales revenue from these therapies in the market.

AC Immune SA Financial Statement Overview

Summary

AC Immune SA shows potential with increasing revenues and improved cash flow management in the latest period. However, consistent profitability remains a challenge due to persistent net losses. The balance sheet is stable with a strong equity position, but operational and financial volatility pose risks.

Income Statement

The company's revenue has shown significant volatility, with revenue increasing from 2022 to 2024. However, profitability remains a concern with negative net income and EBIT margins. The gross profit margin is positive in 2024, indicating some operational efficiency improvement, but net losses persist.

Balance Sheet

AC Immune SA maintains a strong equity base relative to its assets, with a manageable debt-to-equity ratio. However, the company has been accumulating net losses, affecting its return on equity. The equity ratio is healthy, indicating stability in capital structure.

Cash Flow

The cash flow situation shows improvement with a large positive free cash flow in 2024, albeit following a negative trend in prior years. The operating cash flow to net income ratio reflects better cash management, though sustainability remains a question due to historical volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.92M	27.31M	14.80M	3.94M	0.00	15.43M
Gross Profit	28.92M	27.31M	-39.80M	-56.40M	-62.28M	-44.06M
EBITDA	-48.05M	-48.62M	-51.83M	-69.05M	-77.11M	-61.26M
Net Income	-50.51M	-50.92M	-54.23M	-70.75M	-73.00M	-62.10M
Balance Sheet
Total Assets	190.22M	230.91M	182.81M	185.94M	261.44M	238.74M
Cash, Cash Equivalents and Short-Term Investments	127.14M	165.49M	103.05M	122.59M	198.22M	225.89M
Total Debt	4.92M	5.43M	3.50M	2.80M	2.91M	2.22M
Total Liabilities	115.48M	118.64M	22.17M	16.95M	29.46M	23.26M
Stockholders Equity	74.74M	112.27M	160.64M	168.99M	231.98M	215.48M
Cash Flow
Free Cash Flow	-43.62M	65.27M	-61.21M	-74.81M	-68.32M	-61.22M
Operating Cash Flow	-42.62M	65.84M	-60.41M	-73.57M	-65.69M	-59.52M
Investing Cash Flow	21.00M	-105.29M	65.64M	23.76M	-53.66M	28.33M
Financing Cash Flow	-875.00K	-1.12M	43.25M	-1.35M	40.75M	-803.00K

AC Immune SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Positive. The current price of 2.2 is above the 20-day moving average (MA) of 2.14, above the 50-day MA of 2.15, and below the 200-day MA of 2.26, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 52.64 is Neutral, neither overbought nor oversold. The STOCH value of 61.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACIU.

AC Immune SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NBTX	56 Neutral	$420.58M	―	2152.93%	―	―	―
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
ACIU	51 Neutral	$225.59M	―	-50.57%	―	91.44%	18.94%
MOLN	51 Neutral	$142.22M	―	-48.90%	―	-91.15%	-5.82%
IPHA	50 Neutral	$188.28M	―	-160.99%	―	-75.67%	-552.37%
SGMO	46 Neutral	$165.10M	―	-298.41%	―	565.52%	79.44%
IKT	46 Neutral	$123.70M	―	-97.49%	―	-100.00%	62.82%